<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004418</url>
  </required_header>
  <id_info>
    <org_study_id>199/13312</org_study_id>
    <secondary_id>Nutricia-Loma Linda</secondary_id>
    <secondary_id>KKI-FDR000685</secondary_id>
    <nct_id>NCT00004418</nct_id>
  </id_info>
  <brief_title>Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy</brief_title>
  <official_title>Study of Glyceryl Trierucate and Glyceryl Trioleate (Lorenzo's Oil) Therapy in Male Children With Adrenoleukodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate the clinical efficacy of combination glyceryl trierucate and glyceryl&#xD;
      trioleate (Lorenzo's Oil) therapy in boys with X-linked adrenoleukodystrophy.&#xD;
&#xD;
      II. Compare the frequency and severity of neurological disability of study patients with&#xD;
      untreated historical controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is an open label study. Patients must follow dietary instructions as&#xD;
      provided by the investigator. Patients receive 2-4 tablespoons of a mixture of glyceryl&#xD;
      trierucate and glyceryl trioleate oil once daily. Patients complete a neuropsychological&#xD;
      scoring scale questionnaire to measure neurological disability. Patients undergo physical&#xD;
      examinations including magnetic resonance imaging and magnetic resonance spectroscopy of the&#xD;
      head.&#xD;
&#xD;
      Patients are followed monthly for 6 months, then every 3 months until they reach the age of&#xD;
      13 years or death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No funding, move to expanded access&#xD;
  </why_stopped>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Very Long Chain Fatty Acids (VLCFA) Blood Levels</measure>
    <time_frame>Baseline, an average of 10 years, up to age 13</time_frame>
    <description>we will assess the change in very long-chain fatty acids as determined by reduction of blood level baseline C26:0 level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With T2 MRI Abnormality</measure>
    <time_frame>10 years</time_frame>
    <description>We used MRI to determine the number of participants with T2 MRI abnormality indicating childhood Adrenoleukodystrophy (ALD).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Adrenoleukodystrophy</condition>
  <arm_group>
    <arm_group_label>Glyceryl trierucate/glyceryl trioleate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of all enrolled participants. Dosage form is a liquid oil taken orally. Dose is to provide 20% of daily calories. Daily for duration of trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glyceryl trierucate/glyceryl trioleate</intervention_name>
    <description>Administration of glyceryl trierucate/glyceryl trioleate</description>
    <arm_group_label>Glyceryl trierucate/glyceryl trioleate</arm_group_label>
    <other_name>Lorenzo's oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria.&#xD;
&#xD;
          1. Boys between the age of 18 months and 8 years of age&#xD;
&#xD;
          2. Biochemically proven asymptomatic X-linked adrenoleukodystrophy determined by&#xD;
             elevation of very long chain fatty acids or DNA analysis.&#xD;
&#xD;
          3. Platelet count in normal range&#xD;
&#xD;
        Exclusion criteria.&#xD;
&#xD;
          1. Abnormal MRI consistent with childhood cerebral disease&#xD;
&#xD;
          2. Boys who have undergone bone marrow transplantation&#xD;
&#xD;
          3. Other medical condition which in the opinion of the investigator prevents evaluation&#xD;
             or treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>males only</gender_description>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald V Raymond, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-6681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <results_first_submitted>April 13, 2016</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adrenoleukodystrophy</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>rare disease</keyword>
  <keyword>sphingolipidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenoleukodystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>An open trial of Lorenzo's oil spanning decades (1998-2013). Centered at the Kennedy Krieger.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GTO/GTE Treatment</title>
          <description>Intervention: A mixture of glycerol trierucate (GTE) in glycerol trioleate (GTO) in combination with a diet low in saturated fats.&#xD;
GTO/GTE orally; 30-60 ml daily for study period&#xD;
glyceryl trierucate: Glyceryl trierucate is an oil to reduce very long chain fatty acids&#xD;
glyceryl trioleate: Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="126">The definition of completed is until the subject wished to stop taking the oil.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GTO/GTE Treatment</title>
          <description>Intervention: A mixture of glycerol trierucate (GTE) in glycerol trioleate (GTO) in combination with a diet low in saturated fats.&#xD;
GTO/GTE orally; 30-60 ml daily for study period&#xD;
glyceryl trierucate: Glyceryl trierucate is an oil to reduce very long chain fatty acids&#xD;
glyceryl trioleate: Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.25" lower_limit="1.5" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Male children only were eligible for this study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Very Long Chain Fatty Acids (VLCFA) Blood Levels</title>
        <description>we will assess the change in very long-chain fatty acids as determined by reduction of blood level baseline C26:0 level.</description>
        <time_frame>Baseline, an average of 10 years, up to age 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTO/GTE Treatment</title>
            <description>Intervention: A mixture of glycerol trierucate (GTE) in glycerol trioleate (GTO) in combination with a diet low in saturated fats.&#xD;
GTO/GTE orally; 30-60 ml daily for study period&#xD;
glyceryl trierucate: Glyceryl trierucate is an oil to reduce very long chain fatty acids&#xD;
glyceryl trioleate: Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Very Long Chain Fatty Acids (VLCFA) Blood Levels</title>
          <description>we will assess the change in very long-chain fatty acids as determined by reduction of blood level baseline C26:0 level.</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" lower_limit="0.05" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With T2 MRI Abnormality</title>
        <description>We used MRI to determine the number of participants with T2 MRI abnormality indicating childhood Adrenoleukodystrophy (ALD).</description>
        <time_frame>10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTO/GTE Treatment</title>
            <description>Intervention: A mixture of glycerol trierucate (GTE) in glycerol trioleate (GTO) in combination with a diet low in saturated fats.&#xD;
GTO/GTE orally; 30-60 ml daily for study period&#xD;
glyceryl trierucate: Glyceryl trierucate is an oil to reduce very long chain fatty acids&#xD;
glyceryl trioleate: Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With T2 MRI Abnormality</title>
          <description>We used MRI to determine the number of participants with T2 MRI abnormality indicating childhood Adrenoleukodystrophy (ALD).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 years (throughout the study)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GTO/GTE Treatment</title>
          <description>Intervention: A mixture of glycerol trierucate (GTE) in glycerol trioleate (GTO) in combination with a diet low in saturated fats.&#xD;
GTO/GTE orally; 30-60 ml daily for study period&#xD;
glyceryl trierucate: Glyceryl trierucate is an oil to reduce very long chain fatty acids&#xD;
glyceryl trioleate: Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Subject had profound adrenal crisis and died</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>adrenal crisis</sub_title>
                <description>Two events of adrenal crisis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Low platelet count defined as &lt;80, 000</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevation in liver function tests</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerald Raymond</name_or_title>
      <organization>Kennedy Krieger Institute</organization>
      <phone>443-923-2750</phone>
      <email>raymond@kennedykrieger.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

